A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

Table 1 Irazabal equation coefficients for estimating future eGFR

Variable	Description	Value
α	Intercept	21.18
β	Sex (reference is male)	−1.26
γ	Age at HtTKV0 (years)	−0.26
δ	eGFR at HtTKV0 (mL/min per 1.73 m²)	0.90
θc	Subclass 1C	−1.14
θd	Subclass 1D	−1.93
θe	Subclass 1E	−6.26
ε	Years from HtTKV0	−0.23
λ	Sex, years from HtTKV0^a	0.19
μ	Age at HtTKV, years from HtTKV0^a	−0.02
σc	Subclass 1C, years from HtTKV0^a	−2.63
σd	Subclass 1D, years from HtTKV0^a	−3.48
σe	Subclass 1E, years from HtTKV0^a	−4.78

Variables pertaining to Subclass 1B are not presented because these patients were not included in the cohort model
Source: Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M et al.: Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 2015, 26(1):160–172
eGFR Estimated glomerular filtration rate, HtTKV Height-adjusted total kidney volume, HtTKV0 Baseline height-adjusted total kidney volume
^aDenotes interaction terms

ISSN: 1471-2369